Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

November 1, 2007
S-1. An effective adjuvant treatment.... In the US????
By a GLG Expert Contributor
Analysis of: Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine (content.nejm.org)
Taiho Pharmaceutical, Tokyo's oral 5FU relative produces a significant improvement in survival in gastric cancer in Asian patients.
October 31, 2007
Temodar, Schering-Plough Corp., improves survival in Glioblastoma patients....
By a GLG Expert Contributor
Analysis of: Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme (www.pipelinereview.com)
Temodar, ( temozolomide) Schering-Plough Corp., improves survival in Glioblastoma patients when compared to radiation therapy (XRT) alone.
October 31, 2007
So much for Lilly's arzoxifene in breast cancer therapy, but prevention & osteoporosis???
By a GLG Expert Contributor
Analysis of: Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer (jco.ascopubs.org)
     Tamoxifen (AstraZeneca), the original hormone blocker in breast cancer, has lost some of it's cache to aromatase inhibitors & blockers Femara (Novartis), Aromasin (Pfizer) & Arimidex (AstraZeneca), but in this study is more effective than the new kid on the block arzoxifene....
October 30, 2007
Picoplatin- May be a winner, but let's await the trial results.
By a GLG Expert Contributor
Analysis of: Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer (www.prnewswire.com)
Picoplatin is being evaluated for relapsed small cell lung cancer. This may lead to European and later USA acceptance.
October 30, 2007
SF1126- Efficacy?? Lets see how more rodents do......
By a GLG Expert Contributor
Analysis of: Semafore's PI3 Kinase Inhibitor SF1126 Is Active Against Tumor and Tumor cells and Synergizes with Standard Chemeotherapy Agents (www.pipelinereview.com)
In vitro and animal model positivity in killing neoplastic cells.
October 29, 2007
Capecitabine/Tarceva in Pancreatic Ca?
By a GLG Expert Contributor
Analysis of: Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer (jco.ascopubs.org)
That a Xeloda/Tarceva combination will be effective in refractory Gemzar treated pancreatic tumors.
October 25, 2007
Taxotere and H & N Cancer: So Happy Together
By a GLG Expert Contributor
Analysis of: Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer (content.nejm.org)
The addition of Taxotere to standard chemotherapy improves survival compared to the other chemo agents alone +/- Radiation therapy in advanced stage H & N  cancer.
October 23, 2007
Avastin + Chemo has + effect in Glioblastomas (GBM) in a phase II trial
By a GLG Expert Contributor
Analysis of: Avastin seen as helpful against deadly brain tumor (www.reuters.com)
Genentech (and patients) hope that Avastin + chemotherapy will show survival benefit in this disastrous neoplasm.
October 22, 2007
Avastin/Tarceva (Genentech) in Lung Cancer: Synergy? Maybe!
By a GLG Expert Contributor
Analysis of: Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer (jco.ascopubs.org)
"Results for PFS and overall survival favor combination of bevacizumab with either chemotherapy or erlotinib over chemotherapy alone in the second-line setting. "
October 22, 2007
Ixempra. A hit for BMS
By a GLG Expert Contributor
Analysis of: US FDA approves Bristol-Myers breast cancer drug (www.reuters.com)
Now available for use in advanced breast cancer.

Previous Page : 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Next251 to 260 of 457

Analytics


Generated at 2009-01-07T19:00:58.307